Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVAIR DISKUS 100/50 vs ACETASOL HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluticasone propionate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, thereby inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production. Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, increasing c AMP levels, leading to bronchodilation and inhibition of mast cell mediator release.
Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.
Long-term maintenance treatment of asthma in patients aged 4 years and older,Maintenance treatment of chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis,Off-label: Treatment of COPD exacerbations
Treatment of superficial bacterial infections of the external auditory canal (swimmer's ear),Treatment of fungal infections of the external ear
One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart, via oral inhalation.
5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.
Fluticasone propionate: terminal half-life approximately 8 hours (range 4-12 hours) after inhalation; clinical context: supports twice-daily dosing. Salmeterol: terminal half-life approximately 5.5 hours (range 3-10 hours) after inhalation; clinical context: supports twice-daily dosing.
Hydrocortisone has a terminal elimination half-life of approximately 1.5-2 hours. Acetic acid has a half-life of minutes due to rapid metabolism. Clinical context: dosing interval is typically 3-4 times daily for otic use.
Fluticasone propionate undergoes extensive first-pass metabolism via cytochrome P450 3A4 (CYP3A4) to an inactive carboxylic acid metabolite. Salmeterol is metabolized primarily by CYP3A4 to alpha-hydroxysalmeterol.
Not extensively metabolized; undergoes minimal hepatic metabolism.
Fluticasone propionate: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (~5% unchanged), fecal elimination of parent drug and metabolites. Salmeterol: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (about 25% of dose), fecal elimination.
Acetasol HC is a combination product containing hydrocortisone and acetic acid. Hydrocortisone is primarily metabolized in the liver and excreted renally as inactive metabolites; less than 1% is excreted unchanged. Acetic acid is rapidly metabolized via the tricarboxylic acid cycle and eliminated as carbon dioxide and water. Biliary/fecal elimination is negligible for both components.
Fluticasone propionate: approximately 90% bound to plasma proteins (primarily albumin). Salmeterol: approximately 96% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Hydrocortisone is approximately 90-95% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid has negligible protein binding (<10%).
Fluticasone propionate: Vd approximately 4.2 L/kg (range 3-6 L/kg), indicating extensive tissue distribution. Salmeterol: Vd approximately 7 L/kg (range 5-10 L/kg), indicating extensive tissue distribution.
Hydrocortisone Vd is approximately 0.3-0.5 L/kg, indicating distribution into total body water. Acetic acid Vd is approximately 0.4 L/kg. Clinical meaning: limited tissue distribution; primarily remains in extracellular fluid.
Fluticasone propionate: absolute bioavailability from inhaled ADVAIR DISKUS is approximately 18% (range 15-21%), due to lung deposition and low oral bioavailability (<1%). Salmeterol: absolute bioavailability from inhaled ADVAIR DISKUS is approximately 25% (range 20-30%), due to lung deposition; oral bioavailability is negligible.
Otic: Bioavailability is approximately 10-20% via the ear canal due to slow permeation through tympanic membrane; systemic absorption is minimal (<10% of applied dose). Oral: Not applicable; product is for otic use only.
No dosage adjustment required for renal impairment; pharmacokinetics not significantly altered.
No renal adjustment required as systemic absorption is negligible.
Child-Pugh Class A: No adjustment. Child-Pugh Class B and C: Use with caution; consider reduced dose due to increased systemic exposure; monitor for adverse effects.
No hepatic adjustment required as systemic absorption is negligible.
Not recommended for children under 12 years. For adolescents 12 years and older, same as adult dosing: 1 inhalation twice daily.
Same as adult: 5 drops into affected ear(s) 3-4 times daily. Safety and efficacy in children under 2 years not established.
No specific dose adjustment; use lowest effective dose; monitor for systemic corticosteroid effects and cardiovascular events due to salmeterol.
No specific adjustment; use same adult dosing. Consider age-related skin thinning and potential for increased systemic absorption in cases of tympanic membrane perforation.
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Therefore, ADVAIR DISKUS 100/50 should only be used for asthma in patients not adequately controlled on a long-term asthma control medication (e.g., inhaled corticosteroid) or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
None
Increased risk of asthma-related death with LABA use,Cardiovascular effects (e.g., increased blood pressure, tachycardia, arrhythmias),Paradoxical bronchospasm,Hypersensitivity reactions (e.g., anaphylaxis, angioedema),Hypercorticism and adrenal suppression with high doses or prolonged use,Reduced bone mineral density with long-term use,Pneumonia risk in COPD patients,Ketoacidosis in patients with diabetes
For otic use only; not for ophthalmic use,Prolonged use may result in overgrowth of non-susceptible organisms,Discontinue if sensitization or irritation occurs,Caution in patients with perforated tympanic membrane
Primary treatment of status asthmaticus or acute episodes of asthma requiring intensive measures,Hypersensitivity to fluticasone propionate, salmeterol, or any excipient,Severe hypersensitivity to milk proteins (due to lactose content)
Hypersensitivity to any component,Perforated tympanic membrane,Viral or fungal infections of the ear (except when used for fungal infections as indicated)
No specific food interactions; avoid grapefruit juice as it may increase fluticasone systemic absorption. Take with or without food.
No known food interactions. Avoid excessive alcohol as it may impair immune response.
Pregnancy Category C. Fluticasone propionate and salmeterol: No adequate human studies. In animal studies, fluticasone caused fetal toxicity at high doses (cleft palate, reduced fetal weight) at doses ≥30 mcg/kg SC; salmeterol caused delayed ossification and reduced survival at doses ≥1.4 mg/kg PO. First trimester: No data for ADVAIR; avoid unless benefit outweighs risk. Second/third trimester: Use only if clearly needed; monitor fetal growth and consider risk of maternal asthma exacerbation.
ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies in pregnant women. Animal reproduction studies with topical glucocorticoids have shown an increased risk of cleft palate and other malformations at high doses. Based on limited human data and low systemic exposure, use during pregnancy is generally considered low risk. However, as a precaution, avoid use in the first trimester unless clearly needed.
Fluticasone and salmeterol are excreted in breast milk in animals; unknown in humans. M/P ratio not determined. Consider developmental benefits of breastfeeding vs. potential for drug-induced adverse effects. Use caution if benefit to mother outweighs infant risk. For asthma, inhaled doses likely produce minimal systemic exposure, but monitor infant for respiratory symptoms or heart rate changes.
Systemic absorption after otic application is minimal. It is not known whether hydrocortisone or acetic acid is excreted in human milk. M/P ratio is not available. Concentrations in milk are likely negligible. Use is considered compatible with breastfeeding.
No specific dose adjustments are recommended for ADVAIR DISKUS 100/50 during pregnancy. However, pregnancy may alter pharmacokinetics: increased clearance of fluticasone and salmeterol due to elevated blood volume and renal blood flow. Monitor asthma control closely; if deterioration occurs, consider increasing dose or adding other controller therapy. Do not exceed maximum recommended dose (500/50 twice daily).
No dose adjustment is necessary in pregnancy due to minimal systemic absorption. Pharmacokinetic changes in pregnancy are not expected to alter efficacy or safety of this topical otic preparation.
ADVAIR DISKUS 100/50 (fluticasone propionate 100 mcg/salmeterol 50 mcg) is a combination inhaler for maintenance therapy of asthma or COPD; not for acute bronchospasm. Rinse mouth after use to prevent oral candidiasis. Monitor for increased blood pressure, tachycardia, and hypokalemia due to salmeterol. Do not use as monotherapy in asthma without inhaled corticosteroid; salmeterol increases risk of asthma-related death when used alone. Diskus device delivers medication via a breath-activated dry powder; ensure patient breaths in rapidly and deeply.
ACETASOL HC (acetic acid 2%, hydrocortisone 1%) is used for otitis externa. Acetic acid restores acidic p H of ear canal, inhibiting bacterial and fungal growth. Hydrocortisone reduces inflammation and pruritus. Ensure tympanic membrane is intact before use due to risk of ototoxicity with corticosteroids in middle ear. Do not use for more than 7 days. Shake well before instillation.
Use exactly as prescribed; do not use more puffs than directed.,Rinse mouth with water after each use (do not swallow) to prevent thrush.,Do not use for sudden breathing problems; have a rescue inhaler (e.g., albuterol) available.,If you miss a dose, skip it; do not double the dose.,Call your doctor if symptoms worsen or you need more rescue inhaler than usual.,Store diskus at room temperature away from moisture and heat; keep closed when not in use.,Do not stop taking this medicine without consulting your doctor.
Instill 3-4 drops into affected ear every 2-3 hours for 5-7 days.,Lie on side for 5 minutes after instillation to ensure coverage.,Avoid inserting cotton swabs or objects into the ear.,Discontinue if pain, worsening discharge, or rash occurs.,Do not use if ear drum is perforated or if you have a history of ear surgery.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVAIR DISKUS 100/50 vs ACETASOL HC, answered by our medical review team.
ADVAIR DISKUS 100/50 is a Corticosteroid/LABA Combination that works by Fluticasone propionate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, thereby inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production. Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, increasing c AMP levels, leading to bronchodilation and inhibition of mast cell mediator release.. ACETASOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVAIR DISKUS 100/50 and ACETASOL HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVAIR DISKUS 100/50 is: One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart, via oral inhalation.. The standard adult dose of ACETASOL HC is: 5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVAIR DISKUS 100/50 and ACETASOL HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVAIR DISKUS 100/50 is classified as Category C. Pregnancy Category C. Fluticasone propionate and salmeterol: No adequate human studies. In animal studies, fluticasone caused fetal toxicity at high doses (cleft palate, reduced fe. ACETASOL HC is classified as Category C. ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.